(Total Views: 436)
Posted On: 09/10/2019 8:06:28 PM
Post# of 153977
Misiu: Yes GILD is in deep trouble:
- KITE acquisition has not paid the amount of money they invested.
- They have failed with their candidate for NASH
- TRUVADA is now generic and they need to replace (Descovy).
- Has strong competition in ViiV
- GILD is basically now a single-product company (TAF-based products).
- Has greatly under-invested in HIV research.
The solution: Leronlimab !!!!
- KITE acquisition has not paid the amount of money they invested.
- They have failed with their candidate for NASH
- TRUVADA is now generic and they need to replace (Descovy).
- Has strong competition in ViiV
- GILD is basically now a single-product company (TAF-based products).
- Has greatly under-invested in HIV research.
The solution: Leronlimab !!!!
(4)
(0)
